FDA approves Abilify from BMY, Otsuka

The FDA granted marketing approval to Bristol-Myers (BMY) and partner Otsuka (Tokyo, Japan) for Abilify aripiprazole to treat schizophrenia. The companies received an approvable letter for the compoun...